Sign In / Register          (0)
logo
Structure-Based Virtual Screening (SBVS)

Structure-Based Virtual Screening (SBVS)

Structure-based virtual screening (SBVS) exploits three-dimensional structural information of biological targets—typically derived from X-ray crystallography, cryo-electron microscopy, or homology modeling—to computationally evaluate and rank large compound libraries according to predicted binding affinity and complementarity. By explicitly modeling protein-ligand interactions including hydrogen bonds, hydrophobic contacts, van der Waals forces, and electrostatic complementarity, SBVS provides mechanistic insights into binding modes that purely ligand-based approaches cannot offer. Profacgen's SBVS platform integrates state-of-the-art docking algorithms, ensemble-based strategies, and advanced scoring functions to identify high-quality hit compounds across diverse target classes from kinases and proteases to GPCRs and protein-protein interactions.

Our structure-based virtual screening services encompass the complete workflow from target preparation and binding site analysis through compound library screening, hit ranking, and post-processing refinement. We specialize in challenging scenarios including targets with flexible binding pockets, metalloproteins requiring explicit coordination geometry treatment, and membrane proteins where lipophilic environments influence ligand binding. Our computational infrastructure supports screening campaigns ranging from focused libraries of thousands to ultra-large databases exceeding billions of compounds, with hierarchical filtering strategies that balance computational efficiency against prediction accuracy.

Structure-based virtual screening pipeline showing receptor preparation, docking, and scoring workflowFigure 1. Structure-Based Virtual Screening work-flow. (Lionta et al., 2014)

Foundations of Structure-Based Drug Design

SBVS is rooted in Fischer’s lock-and-key model, later refined to include induced-fit, conformational selection, and allosteric modulation. The core premise—that ligand activity correlates with binding free energy—underpins all structure-based approaches. Docking algorithms approximate ΔGbind by evaluating enthalpic terms (van der Waals, H-bonds, electrostatics) and simplified entropy contributions (conformational strain, desolvation, rotational/translational costs).

Search strategies include deterministic, stochastic (Monte Carlo, genetic algorithms), or hybrid methods. Scoring functions fall into force-field-based, empirical, knowledge-based, and machine-learning categories. Profacgen employs multi-scoring consensus protocols to improve hit identification beyond any single function.

Our Structure-Based Virtual Screening Services

High-Throughput Molecular Docking

Large-scale virtual screening using Glide SP/XP, AutoDock Vina, GOLD, or LeDock with optimized protocol parameters. Library filtering by physicochemical properties, pharmacophore constraints, and shape matching prior to docking. Parallel computing on GPU clusters enables screening of billion-compound libraries within feasible timelines.

Induced-Fit Docking (IFD)

Iterative docking protocols that refine binding site side chains and backbone segments during ligand placement. Glide IFD and Schrodinger workflows model protein conformational changes upon ligand binding. Critical for targets known to undergo significant pocket rearrangements including kinases and nuclear receptors.

Ensemble Docking and Conformational Sampling

Docking against multiple crystallographic or MD-generated receptor conformations captures binding site dynamics. Consensus scoring across ensemble members identifies compounds robustly predicted to bind across conformational states. Essential for flexible targets including GPCRs, kinases with DFG-loop mobility, and protein-protein interaction sites.

Molecular Dynamics (MD) Refinement and Free Energy Calculations

Post-docking refinement using explicit-solvent MD simulations to validate binding pose stability. MM-GBSA/PBSA rescoring provides improved affinity ranking for top hits. Free energy perturbation (FEP) calculations offer quantitative relative binding affinity predictions for lead optimization, achieving <1 kcal/mol accuracy in favorable cases.

Machine Learning Scoring and Rescoring

Neural network scoring functions (NNScore, RF-Score, DeepDock) trained on protein-ligand structural data improve discrimination between true binders and decoys. OnionNet, IGN, and GraphBar architectures process atomic environments and interaction graphs for affinity prediction. Consensus schemes combining physics-based and ML scores optimize enrichment factors.

Covalent Docking and Metalloprotein Screening

Specialized protocols for covalent inhibitors including warhead placement, reaction mechanism modeling, and reversible/irreversible binding treatment. Metalloprotein docking with explicit metal coordination constraints and customized force fields for zinc, iron, copper, and magnesium centers. Supports cysteine, serine, lysine, and tyrosine-targeting covalent ligands.

Applications

Key Advantages of Our SBVS Service

  • Cutting-Edge Software Portfolio: We deploy industry-leading docking platforms including AutoDock Vina, Glide, GOLD, rDock, and OpenEye toolkits, ensuring access to the most accurate and well-validated methods available.
  • Integrated In Silico & Experimental Expertise: Our team combines deep computational chemistry experience with practical drug discovery knowledge, bridging the gap between in silico predictions and experimental outcomes.
  • High-Performance Computing Infrastructure: Our computing cluster delivers rapid throughput for ultra-large screens, enabling millions of docking evaluations within practical timeframes without compromising sampling quality.
  • Flexibility Across Target Classes: From soluble enzymes to membrane proteins, from protein–protein interfaces to allosteric pockets—our protocols are adapted to the unique challenges posed by each target class.
  • Actionable Deliverables: Beyond ranked hit lists, we provide binding mode visualizations, interaction analyses, synthetic feasibility assessments, and clear recommendations for next-step experimental planning.

Representative Case Studies

Case 1: Novel Kinase Inhibitor Identification Through SBVS

Program Context:

A pharmaceutical company sought novel ATP-competitive inhibitors for a therapeutically relevant kinase target where existing patents created crowded IP space around known chemotypes. The available X-ray co-crystal structure offered a well-defined binding pocket but limited opportunities for scaffold-hopping within the known chemical series.

Objective:

To identify structurally novel, synthetically accessible kinase inhibitor candidates occupying the same ATP-binding site as reference ligands, with predicted nanomolar affinity and favorable selectivity profiles against off-target kinases.

Approach:

We executed an SBVS campaign against a curated library of ~3 million commercially available compounds. The workflow included multi-conformer docking with induced-fit sampling, consensus scoring across four independent functions, MM-GBSA rescoring of the top 5,000 hits, and selectivity filtering against a panel of 50 off-target kinases using rapid cross-docking.

Outcome:

The screen delivered 42 high-confidence hits representing six distinct chemotype families absent from the patent landscape. Twenty compounds were procured and tested; 8 confirmed activity with IC50 values below 1 μM, including two sub-100 nM leads that advanced to hit-to-lead optimization.

Case 2: Fragment-Based SBVS for a Challenging Protein–Protein Interaction Target

Program Context:

A research program targeted a protein–protein interaction (PPI) interface with no known small-molecule modulators. The interface was large, flat, and featureless by conventional standards—a notoriously difficult class for small-molecule intervention. Traditional HTS had yielded no tractable hits.

Objective:

To identify low-molecular-weight fragments binding to cryptic or transient pockets on the PPI surface that could serve as starting points for fragment-growing or linking strategies.

Approach:

We employed fragment-optimized SBVS protocols using dedicated fragment scoring functions and enhanced sampling of surface-exposed sub-pockets. Ensemble docking was performed across 20 MD-derived receptor conformations to capture binding site plasticity. Top-ranked fragments underwent water-map analysis and hotspot residue identification.

Outcome:

The campaign identified 18 validated fragment hits with confirmed binding by NMR or SPR. Three fragments bound to adjacent subsites suitable for structure-guided fragment linking, providing a viable path forward for a target previously considered "undruggable."

Request a Quote

Frequently Asked Questions (FAQs)

Q: What is the difference between SBVS and LBVS?
A: Structure-Based Virtual Screening (SBVS) docks compounds directly into a 3D target structure and ranks them by binding affinity predictions. Ligand-Based Virtual Screening (LBVS) uses known active compounds as references and searches for molecules with similar pharmacophoric features, shapes, or fingerprint profiles without requiring a target structure. Both approaches have complementary strengths—SBVS excels when high-quality structural information is available, while LBVS is valuable when multiple known actives exist but structural data is lacking.
A: Our infrastructure supports screening campaigns ranging from thousands to tens of millions of compounds. For standard projects, we typically screen commercial libraries containing 1–10 million molecules. For focused libraries or fragment collections, even larger effective coverage can be achieved through systematic enumeration of combinatorial libraries around core scaffolds of interest.
A: We employ multiple strategies to address receptor flexibility: (1) Ensemble docking using multiple experimental structures or MD-generated conformations; (2) Induced-fit docking with side-chain rearrangement during pose optimization; (3) Soft-receptor potentials allowing modest steric overlap to accommodate subtle backbone adjustments; and (4) Post-docking relaxation via short MD simulations for final candidates. The choice depends on target characteristics and project requirements.
A: Turnaround depends heavily on library size, target complexity, and the depth of post-processing required. A standard SBVS campaign (1–5 million compounds, single-structure rigid-receptor docking with consensus scoring) typically requires 2–4 weeks from project kickoff to hit-list delivery. Projects involving extensive flexibility handling, free-energy calculations, or custom library preparation may extend to 6–8 weeks.
A: Yes. We regularly perform SBVS against GPCRs, ion channels, transporters, and other membrane proteins using either experimental structures (from X-ray crystallography or cryo-EM) or carefully validated homology models. Special attention is given to membrane environment effects, lipid-exposed binding sites, and the unique physicochemical properties of membrane-embedded targets.
A: We conduct retrospective validation using benchmark sets containing known active compounds and property-matched decoys. Key metrics include Enrichment Factor (EF) at 1% and 5%, ROC-AUC, Boltzmann-Enhanced Discrimination of Receiver Operating Characteristic (BEDROC), and Hit Rate. These metrics quantify how effectively the scoring function enriches true actives near the top of the ranked list compared to random selection.

References:

  1. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem. 2014;14(16):1923-1938. doi:10.2174/1568026614666140929124445
Online Inquiry

Fill out this form and one of our experts will respond to you within one business day.